Quick answer
Traditional Chinese medicine has treated rheumatoid arthritis for centuries, but the evidence base was thin: small series, inconsistent outcome measures, no long-term follow-up. Jiang Quan's rheumatology department at Guang'anmen Hospital addressed that with infrastructure — China's first ten-thousand-patient cohort of TCM-treated RA, a registry that follows patients over time with standard measures. The resulting framework has been applied in 1,850 institutions across 31 provinces and won a 2024 Chinese Association of TCM science and technology first prize [1][3][5].
Key takeaways
- Cohort: the first ten-thousand-level cohort of TCM-treated rheumatoid arthritis in China [1][3].
- Registry: built on CERTAIN, the Chinese rheumatology TCM registration platform [6].
- Real-world analysis: 2,506 cases stratified by disease duration — under 6 months, 6 months to 5 years, and 5 to 20 years [6].
- Dissemination: framework applied in 1,850 institutions in 31 provinces, with 22,000 clinicians trained and over 1 million patients reached [2].
- Award: 2024 Chinese Association of TCM science and technology prize, first class, for establishing and applying the RA diagnosis-and-treatment system [1][2].
Why a cohort is the right instrument here
Rheumatoid arthritis is chronic, relapsing and treated over decades, and the outcomes that matter — joint destruction, disability, organ damage — accumulate slowly. A registry with repeated measurement can show whether a treatment strategy alters that trajectory in ordinary practice, which a short randomised trial of symptom scores cannot [1][5].
The intellectual contribution is a shift in therapeutic emphasis. The team argued that active RA is dominated by a damp-heat with stasis pattern rather than the classical wind-cold-damp framing, and that clearing heat and invigorating blood protects bone — a move from warming to cooling approaches that they describe as a theoretical advance in the field [4].
What registry evidence can and cannot establish
A ten-thousand-patient cohort is a substantial asset, and the real-world analysis by disease duration adds something trials rarely provide: how patients at different stages respond [6].
Patients who stay in a TCM registry are those who continue TCM, so the cohort enriches for responders — survivorship bias that inflates apparent benefit. Most patients also take conventional disease-modifying drugs, so separating the herbal contribution from background therapy is not possible observationally. Registry data can generate hypotheses and support coverage decisions; they cannot establish efficacy, which still requires randomised trials with blinded outcome assessment and radiographic endpoints. The dissemination figures measure adoption, not effectiveness [2][6].
The condition in context: rheumatoid arthritis
It affects roughly 0.5–1% of adults and is a leading cause of preventable disability.
| Region | What the data shows | Source |
|---|---|---|
| Core problem | Bone destruction causes disability; organ involvement causes death [1]. | Guang'anmen Hospital [1] |
| Treatment gap | Conventional therapy controls inflammation but does not eliminate progression in all patients [4]. | Toutiao feature [4] |
| Department pedigree | Founded in 1981 under Zhao Jinduo, Lu Zhizheng and Xie Haizhou; helped create the national TCM rheumatology society [3]. | Hospital profile [3] |
Because RA requires decades of treatment, a strategy that is safe and affordable over that horizon has value beyond short-term symptom control [5].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Evidence infrastructure | A cohort with longitudinal follow-up where none existed [1][3]. | [1][3] |
| Standardisation | A framework applied nationally [2]. | [2] |
| Caution | Observational; adoption is not efficacy [6]. | [6] |
Availability and limits
- This is an editorial summary of hospital and award reporting, not a treatment recommendation [1][2].
- Cohort data are observational and subject to selection bias [6].
- Most patients also receive conventional DMARDs [4].
- Herbal formulae vary in composition between manufacturers [3].
- Radiographic progression endpoints are not the focus of the registry reports [6].
What to ask before booking
| Question | Why it matters |
|---|---|
| Will I continue conventional disease-modifying therapy? | TCM is used alongside, not instead of, DMARDs [4]. |
| How will joint damage be monitored? | Radiographic progression is the outcome that matters [1]. |
| Which department handles foreign patients, and in what language? | Guang'anmen is a working hospital we do not book; confirm international-department coordination and language support. |
| What evidence supports the specific formula offered? | Cohort evidence is not trial evidence [6]. |
Questions patients ask
What was built?
China's first ten-thousand-level cohort of TCM-treated rheumatoid arthritis, with a panoramic diagnosis-and-treatment framework derived from it [1][3].
What did the real-world analysis show?
A study of 2,506 cases stratified by disease duration described pattern distribution and treatment response at different stages [6].
How widely is it used?
Applied in 1,850 institutions across 31 provinces, with 22,000 clinicians trained and over 1 million patients reached [2].
Does it prove TCM works?
No — it is observational registry evidence, which supports hypotheses and practice standardisation but not efficacy claims [6].
Is this relevant to international patients?
It is useful context for China's integrative rheumatology. The hospital is a working hospital we do not book — contact its international department directly [1].